MX2016010169A - Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina. - Google Patents

Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.

Info

Publication number
MX2016010169A
MX2016010169A MX2016010169A MX2016010169A MX2016010169A MX 2016010169 A MX2016010169 A MX 2016010169A MX 2016010169 A MX2016010169 A MX 2016010169A MX 2016010169 A MX2016010169 A MX 2016010169A MX 2016010169 A MX2016010169 A MX 2016010169A
Authority
MX
Mexico
Prior art keywords
cgrp
active compounds
tablet formulation
api
formula
Prior art date
Application number
MX2016010169A
Other languages
English (en)
Inventor
Xu Wei
NOFSINGER Rebecca
LUPTON Lisa
ann johnson Mary
Resende ALLAIN Leonardo
Mark Eickhoff W
B Ikeda Craig
D Brown Chad
J Jr Flanagan Francis
Marota Melanie
B Patel Paresh
XI Hanmi
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53778348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016010169(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2016010169A publication Critical patent/MX2016010169A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Abstract

La presente invención está dirigida a composiciones que comprenden un material extrudido o solución sólida de un compuesto, o una sal del mismo, de fórmula I (API): fórmula I, (ver Fórmula) en donde ``Ra´´ es independientemente H o -F, en una matriz de polímero soluble en agua, la cual comprende adicionalmente un sistema de desintegración que permite que una tableta obtenida del mismo se desintegre rápidamente en el ambiente en el cual el API será liberado.
MX2016010169A 2014-02-05 2015-01-30 Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina. MX2016010169A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461936019P 2014-02-05 2014-02-05
US201462087366P 2014-12-04 2014-12-04
PCT/US2015/013672 WO2015119848A1 (en) 2014-02-05 2015-01-30 Tablet formulation for cgrp-active compounds

Publications (1)

Publication Number Publication Date
MX2016010169A true MX2016010169A (es) 2016-10-07

Family

ID=53778348

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016010169A MX2016010169A (es) 2014-02-05 2015-01-30 Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.
MX2021006790A MX2021006790A (es) 2014-02-05 2016-08-04 Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006790A MX2021006790A (es) 2014-02-05 2016-08-04 Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.

Country Status (13)

Country Link
US (4) US10117836B2 (es)
EP (1) EP3102564A4 (es)
JP (2) JP6491669B2 (es)
KR (3) KR20220136460A (es)
CN (2) CN105960397B (es)
AU (4) AU2015214502B2 (es)
CA (1) CA2937315A1 (es)
HK (1) HK1232218A1 (es)
IL (1) IL246828B (es)
MX (2) MX2016010169A (es)
RU (2) RU2696578C1 (es)
SA (1) SA516371613B1 (es)
WO (1) WO2015119848A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI522355B (zh) * 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
CN105960397B (zh) 2014-02-05 2020-09-04 默沙东公司 Cgrp-活性化合物的片剂制剂
CN105126111A (zh) * 2015-09-30 2015-12-09 清华大学 提高索拉非尼生物利用度的制剂
CN110446707B (zh) * 2017-03-30 2024-03-08 默克专利股份公司 药物制剂
US20210000814A1 (en) * 2018-03-25 2021-01-07 Biohaven Pharmaceutical Holding Company Ltd. Rimegepant for cgrp related disorders
RU2755571C1 (ru) * 2020-06-09 2021-09-17 Сергей Геннадьевич Каплунов Способ изготовления гравюры на металле
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US20040076668A1 (en) 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
ATE509019T1 (de) 2003-03-14 2011-05-15 Merck Sharp & Dohme Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten
JP4690313B2 (ja) 2003-03-14 2011-06-01 メルク・シャープ・エンド・ドーム・コーポレイション カルボキサミドスピロヒダントインｃｇｒｐ受容体アンタゴニスト
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
US8003792B2 (en) 2004-09-13 2011-08-23 Merck Sharp & Dohme Corp. Bicyclic anilide spirolactam CGRP receptor antagonists
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
WO2006099268A2 (en) 2005-03-14 2006-09-21 Merck & Co., Inc. Cgrp receptor antagonists
JP5773560B2 (ja) 2006-02-09 2015-09-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｅｔｐ阻害剤のポリマー製剤
CA2650932C (en) 2006-05-09 2013-01-22 Merck & Co., Inc. Substituted spirocyclic cgrp receptor antagonists
ES2504565T3 (es) 2007-06-05 2014-10-08 Merck Sharp & Dohme Corp. Antagonistas del receptor CGRP de carboxamida heterocíclica
WO2009050234A1 (de) 2007-10-18 2009-04-23 Boehringer Ingelheim International Gmbh Cgrp-antagonisten
EP2225237A2 (de) 2007-11-22 2010-09-08 Boehringer Ingelheim International GmbH Organische verbindungen
JP2011511792A (ja) 2008-02-05 2011-04-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体アンタゴニストのプロドラッグ
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
CN102065842A (zh) 2008-04-15 2011-05-18 先灵公司 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物
PL2732818T3 (pl) * 2009-03-31 2017-12-29 Ligand Pharmaceuticals Inc. Bifenylosulfonamidowy antagonista receptora endoteliny i angiotensyny II do leczenia stwardnienia kłębków nerkowych
EP2438067B1 (de) 2009-06-05 2015-08-26 Boehringer Ingelheim International GmbH Spirolactame als cgrp-antagonisten
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
TWI522355B (zh) 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
AU2011326455A1 (en) 2010-11-12 2013-05-23 Merck Sharp & Dohme Corp. Piperidinone carboxamide indane CGRP receptor antagonists
EP2654421B1 (en) 2010-12-22 2016-10-19 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide as cgrp receptor antagonists
EP2654423B1 (en) 2010-12-22 2016-12-07 Merck Sharp & Dohme Corp. Fused heterocyclic azaindane carboxamide cgrp receptor antagonists
EP2654726A4 (en) * 2011-03-08 2013-10-30 Zalicus Pharmaceuticals Ltd SOLID DISPERSION FORMULATIONS AND METHODS OF USE
US9409916B2 (en) 2011-03-18 2016-08-09 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin CGRP receptor antagonists
CN103998461B (zh) 2011-09-08 2018-02-02 科德克希思公司 用于合成取代的内酰胺的生物催化剂和方法
ES2650608T3 (es) 2011-10-14 2018-01-19 Array Biopharma, Inc. Dispersión sólida
WO2013138413A1 (en) 2012-03-14 2013-09-19 Merck Sharp & Dohme Corp. Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
US9487523B2 (en) 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
KR102074013B1 (ko) 2012-04-25 2020-02-05 이노버스 파마슈티컬스, 인코포레이티드 민감화 조성물 및 이용 방법
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
WO2013169574A2 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Aliphatic spirolactam cgrp receptor antagonists
WO2013169563A1 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
US9296750B2 (en) 2012-05-09 2016-03-29 Merck Sharp & Dohme Corp. Spirolactam CGRP receptor antagonists
CA3119755A1 (en) 2013-03-15 2014-09-18 Tonix Pharma Holdings Limited Eutectic formulations of amitriptyline hydrochloride and mannitol
CN112545981A (zh) 2013-09-16 2021-03-26 默沙东公司 用于cgrp受体拮抗剂的制剂
WO2015120014A1 (en) 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
CN105960397B (zh) 2014-02-05 2020-09-04 默沙东公司 Cgrp-活性化合物的片剂制剂
JP2017512757A (ja) 2014-02-24 2017-05-25 ウリゲン ファーマシューティカルズ、インコーポレイテッド 経口投与するためのペントサンポリ硫酸塩の組成物および使用の方法
CN106794185A (zh) 2014-08-22 2017-05-31 克洛维斯肿瘤有限公司 Rucaparib的高剂量强度片剂
CN107427493A (zh) 2015-01-23 2017-12-01 格吕伦塔尔有限公司 用于治疗肝功能受损和/或肾功能受损的受试者的疼痛的Cebranopadol
US20170088612A1 (en) 2015-09-24 2017-03-30 Teva Pharmaceuticals International Gmbh Preventing, treating, and reducing (persistent) post-traumatic headache
US20180092899A1 (en) 2016-09-30 2018-04-05 Merck Sharp & Dohme Corp. Method of treating acute migraine with cgrp-active compound
CN110621343A (zh) 2017-03-02 2019-12-27 贝丝以色列女执事医疗中心 选择对针对降钙素基因相关肽的抗体有反应的头痛患者
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US20190135927A1 (en) 2017-09-29 2019-05-09 Bhl Patent Holdings, Llc Migraine, headache, chronic pain treatment, and prophylaxis options
US20190374518A1 (en) 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US20190374520A1 (en) 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
WO2020214906A1 (en) 2019-04-18 2020-10-22 Allergan Sales, Llc Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo
US20220340650A1 (en) 2019-09-25 2022-10-27 Abnijeet JAKATE Combination therapy with cgrp antagonists
WO2022026767A1 (en) 2020-07-29 2022-02-03 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
US20230130736A1 (en) 2021-09-27 2023-04-27 Allergan Pharmaceuticals International Limited Methods of treating migraine

Also Published As

Publication number Publication date
RU2019123406A (ru) 2019-10-03
CN112022818A (zh) 2020-12-04
JP2017505306A (ja) 2017-02-16
CN105960397A (zh) 2016-09-21
CN105960397B (zh) 2020-09-04
AU2019226239B2 (en) 2021-07-08
RU2696578C1 (ru) 2019-08-05
BR112016017999A2 (es) 2017-08-08
JP6666490B2 (ja) 2020-03-13
CA2937315A1 (en) 2015-08-13
JP2019108366A (ja) 2019-07-04
BR112016017999A8 (pt) 2023-04-11
US20160346214A1 (en) 2016-12-01
KR20230107902A (ko) 2023-07-18
KR20160113296A (ko) 2016-09-28
KR20220136460A (ko) 2022-10-07
JP6491669B2 (ja) 2019-03-27
EP3102564A1 (en) 2016-12-14
HK1232218A1 (zh) 2018-01-05
US20210085612A1 (en) 2021-03-25
MX2021006790A (es) 2021-07-15
AU2015214502B2 (en) 2019-06-06
IL246828B (en) 2019-05-30
US20190209478A1 (en) 2019-07-11
US10117836B2 (en) 2018-11-06
WO2015119848A1 (en) 2015-08-13
US11925709B2 (en) 2024-03-12
KR102448369B1 (ko) 2022-09-28
SA516371613B1 (ar) 2021-06-19
AU2015214502A1 (en) 2016-07-21
US20230248655A1 (en) 2023-08-10
AU2023258317A1 (en) 2023-11-16
EP3102564A4 (en) 2017-10-18
IL246828A0 (en) 2016-08-31
AU2019226239A1 (en) 2019-09-26
AU2021245229A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
MX2021006790A (es) Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
WO2016105564A8 (en) Quinazoline derivatives used to treat hiv
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2017014035A (es) Formas solidas novedosas.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12016501462A1 (en) Neprilysin inhibitors
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
ZA201701384B (en) Compound targeting il-23a and tnf-alpha and uses thereof
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2019004294A (es) Derivados de fenilamina 4-sustituidos y su uso para proteger cultivos al combatir microorganismos fitopatogenicos indeseados.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
MX2017007377A (es) Compuestos organicos.
PH12018501709A1 (en) Naphthridinedione derivatives
PH12018500151A1 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
MX2017007380A (es) Compuestos organicos.
WO2016057660A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2016011572A (es) Composiciones antimicrobianas de acido organico.